<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01201096</url>
  </required_header>
  <id_info>
    <org_study_id>NEO-LEBE</org_study_id>
    <nct_id>NCT01201096</nct_id>
  </id_info>
  <brief_title>Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)</brief_title>
  <acronym>NEO-LEBE</acronym>
  <official_title>Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jena</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to show the tumor free long term survival of patients with
      isolated non-resectable liver metastases of neuroendocrine tumors after neo-adjuvant radio
      receptor treatment and following liver transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Matching patient will be treated neo-adjuvant at the hospital with 177 Lutetium peptide
      receptor radiotherapy in two following courses. After this treatment it will follow the liver
      transplantation within 9 month as postmortal or living donor liver transplantation.

      Under certain conditions concerning the evaluation examinations patients can be included in
      the study.

      Most important factors are no evidence of disease outside the liver, removed primary tumor,
      patients between 18 and 60 years, no curative surgical resection of the liver metastasis
      possible.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>tumor free survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Liver</condition>
  <condition>Metastasis</condition>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>peptide radioreceptor therapy and liver transplantation</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>177Lutetium</intervention_name>
    <description>two cycles of 177Lutetium radioreceptor therapy within two month</description>
    <arm_group_label>peptide radioreceptor therapy and liver transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver transplantation</intervention_name>
    <description>about 9 month after finishing the receptor therapy liver transplantation takes place</description>
    <arm_group_label>peptide radioreceptor therapy and liver transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with liver metastasis of neuroendocrine tumors of the small bowel, colon,
        pancreas or stomach. Primary tumor removed.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 to 60 years

          -  neuroendocrine Tumor with low or intermediate malignant histological appearance

          -  primary tumor removed, no extrahepatic tumor

          -  liver metastasis not resectable

          -  positive evaluation for liver transplantation

          -  primary tumor drained by vena porta

          -  tumor load within the liver &lt; 50%

          -  stable disease after receptor therapy with 177 Lutetium for 6 month

        Exclusion Criteria:

          -  prognostic relevant second tumor disease

          -  pregnancy

          -  undifferentiated neuroendocrine carcinoma (WHO II, G3)

          -  renal insufficiency &gt; second degree

          -  progressive carcinoid conditioned heart disease (&gt;NYHA II)

          -  Karnofsky-Index &lt; 60
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Wurst, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of general-, visceral- and vascular surgery, University of Jena</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dieter Hörsch, Prof. Dr. med</last_name>
    <role>Study Director</role>
    <affiliation>Zentrum für neuroendokrine Tumore, Zentralklinik Bad Berka</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Utz Settmacher, Prof. Dr. med.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of general-, visceral- and vascular surgery, University of Jena</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R. B. Baum, Prof.Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center of neuroendocrine tumors, Zentralklinik Bad Berka</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Wurst, Dr. med.</last_name>
    <phone>00493641</phone>
    <phone_ext>9322450</phone_ext>
    <email>christine.wurst@med.uni-jena.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Utz Settmacher, Prof. Dr. med</last_name>
    <phone>00493641</phone>
    <phone_ext>9322601</phone_ext>
    <email>AVG@med.uni-jena.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for neuroendokrine tumors, Zentralklinik Bad Berka</name>
      <address>
        <city>Bad Berka</city>
        <state>Thüringen</state>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dieter Hörsch, PD Dr. med.</last_name>
      <phone>004936458</phone>
      <phone_ext>52601</phone_ext>
      <email>dieter.hoersch@zentralklinik.bad-berka.de</email>
    </contact>
    <contact_backup>
      <last_name>R. P. Baum, Prof.Dr.med.</last_name>
      <phone>004936458</phone>
      <phone_ext>53515</phone_ext>
      <email>r.baum.pet@zentralklinik-bad-berka.de</email>
    </contact_backup>
    <investigator>
      <last_name>Dieter Hoersch, Prof. Dr. med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of general-, visceral- and vascular surgery, University of Jena</name>
      <address>
        <city>Jena</city>
        <state>Thüringen</state>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Wurst, Dr.med.</last_name>
      <phone>00493641</phone>
      <phone_ext>9322450</phone_ext>
      <email>christine.wurst@med.uni-jena.de</email>
    </contact>
    <contact_backup>
      <last_name>Utz Settmacher, Prof.Dr. med</last_name>
      <phone>00493641</phone>
      <phone_ext>9322601</phone_ext>
      <email>AVG@med.uni-jena.de</email>
    </contact_backup>
    <investigator>
      <last_name>Christine Wurst, Dr.med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.avc.uniklinikum-jena.de/Klinik.html</url>
    <description>official site of the department of general-, visceral- and vascular surgery, University of Jena</description>
  </link>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2010</study_first_submitted>
  <study_first_submitted_qc>September 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2010</study_first_posted>
  <last_update_submitted>September 22, 2010</last_update_submitted>
  <last_update_submitted_qc>September 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. med. Christine Wurst</name_title>
    <organization>Department of General-, Visceral- and Vascularsurgery, University of Jena</organization>
  </responsible_party>
  <keyword>neuroendocrine tumor</keyword>
  <keyword>liver metastasis</keyword>
  <keyword>peptide receptor therapy</keyword>
  <keyword>gastro-entero-pancreatic system</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

